Is major depressive disorder a metabolic encephalopathy?

被引:30
作者
Harvey, Brian H. [1 ]
机构
[1] North West Univ, Sch Pharm, Div Pharmacol, Unit Drug Res & Dev, ZA-2520 Potchefstroom, South Africa
关键词
metabolic encephalopathy; major depression; glutamate; nitric oxide; GABA; antidepressant; onset of action; serotonin;
D O I
10.1002/hup.946
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Metabolic encephalopathy is an acute disturbance in cellular metabolism in the brain evoked by conditions of hypoxia, hypoglycaemia, oxidative stress and/or inflammation. It usually develops acutely or subacutely and is reversible if the systemic disorder is treated. If left untreated, however, metabolic encephalopathy may result in secondary structural damage to the brain. Most encephalopathies are present with neuropsychiatric symptoms, one in particular being depression. However, mood disorders are often co-morbid with cardiovascular, liver, kidney and endocrine disorders, while increasing evidence concurs that depression involves inflammatory and neurodegenerative processes. This would suggest that metabolic disturbances resembling encephalopathy may underscore the basic neuropathology of depression at a far deeper level than currently realized. Viewing depression as a form of encephalopathy, and exploiting knowledge gleaned from our understanding of the neurochemistry and treatment of metabolic encephalopathy, may assist in our understanding of the neurobiology of depression, but also in realizing new ideas in the pharmacotherapy of mood disorders. Copyright (c) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:371 / 384
页数:14
相关论文
共 175 条
[1]
The neurosteroid system: an emerging therapeutic target for hepatic encephalopathy [J].
Ahboucha, Samir ;
Butterworth, Roger F. .
METABOLIC BRAIN DISEASE, 2007, 22 (3-4) :291-308
[2]
Hepatic encephalopathy: molecular mechanisms underlying the clinical syndrome [J].
Albrecht, J ;
Jones, EA .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 170 (02) :138-146
[3]
Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression [J].
Altamura, C ;
Maes, M ;
Dai, J ;
Meltzer, HY .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1995, 5 :71-75
[4]
Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges [J].
Apelqvist, G ;
Wikell, C ;
Hindfelt, B ;
Bergqvist, PBF ;
Andersson, G ;
Bengtsson, F .
PSYCHOPHARMACOLOGY, 1999, 143 (04) :408-416
[5]
A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes [J].
Barbosa, L ;
Berk, M ;
Vorster, M .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (04) :403-407
[6]
ELEVATED BRAIN CONCENTRATIONS OF 1,4-BENZODIAZEPINES IN FULMINANT HEPATIC-FAILURE [J].
BASILE, AS ;
HUGHES, RD ;
HARRISON, PM ;
MURATA, Y ;
PANNELL, L ;
JONES, EA ;
WILLIAMS, R ;
SKOLNICK, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (07) :473-478
[7]
AMELIORATION OF HEPATIC-ENCEPHALOPATHY BY PHARMACOLOGICAL ANTAGONISM OF THE GABA-A-BENZODIAZEPINE RECEPTOR COMPLEX IN A RABBIT MODEL OF FULMINANT HEPATIC-FAILURE [J].
BASSETT, ML ;
MULLEN, KD ;
SKOLNICK, P ;
JONES, EA .
GASTROENTEROLOGY, 1987, 93 (05) :1069-1077
[8]
Tryptophan depletion and its implications for psychiatry [J].
Bell, C ;
Abrams, J ;
Nutt, D .
BRITISH JOURNAL OF PSYCHIATRY, 2001, 178 :399-405
[9]
Mirtazapine compared with paroxetine in major depression [J].
Benkert, O ;
Szegedi, A ;
Kohnen, R .
JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (09) :656-663
[10]
A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia [J].
Benkert, O ;
Grunder, G ;
Wetzel, H ;
Hackett, D .
JOURNAL OF PSYCHIATRIC RESEARCH, 1996, 30 (06) :441-451